BiotechTube

Suvorexant

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Restless Legs Syndrome

Conditions

Restless Legs Syndrome, Insomnia, Sleep Disorder

Trial Timeline

Aug 12, 2021 → Oct 20, 2023

NCT ID
NCT04706091

About Suvorexant

Suvorexant is a approved stage product being developed by Merck for Restless Legs Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04706091. Target conditions include Restless Legs Syndrome, Insomnia, Sleep Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (5)

NCT IDPhaseStatus
NCT04706091ApprovedCompleted
NCT02849184ApprovedCompleted
NCT02704754ApprovedCompleted
NCT01059851Phase 1Completed
NCT01043926Phase 1Completed

Competing Products

20 competing products in Restless Legs Syndrome

See all competitors
ProductCompanyStageHype Score
Gabapentin enacarbilAstellas PharmaApproved
85
ASP8825Astellas PharmaPhase 3
77
RegniteAstellas PharmaPre-clinical
23
ASP8825 + PlaceboAstellas PharmaPhase 2
52
Placebo + Gabapentin enacarbilAstellas PharmaApproved
85
Apomorphine Sublingual Film + PlaceboSumitomo PharmaApproved
85
CabergolinePfizerPhase 3
76
Placebo + pregabalin + pregabalinPfizerPhase 3
76
placebo + Pregabalin + Pregabalin + Pregabalin + Pregabalin + PregabalinPfizerPhase 2
51
pregabalin + placebo + pramipexolePfizerPhase 3
76
placebo and pregabalin + pramipexol + pramipexol + Pregabalin + pramipexol + pramipexolPfizerPhase 3
76
cabergoline + levodopaPfizerPhase 3
76
RotigotineUCBPhase 3
74
Neupro®UCBPre-clinical
20
Rotigotine Nasal SprayUCBPhase 2
49
RotigotineUCBPhase 3
74
Levetiracetam (Keppra)UCBPhase 2
49
Rotigotine + PlaceboUCBApproved
82
RotigotineUCBPhase 2
49
RotigotineUCBPhase 3
74

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85